Details

Autor(en) / Beteiligte

• Thabit, Hood
• Tauschmann, Martin
• Allen, Janet M
• Leelarathna, Lalantha
• Hartnell, Sara
• Wilinska, Malgorzata E
• Acerini, Carlo L
• Dellweg, Sibylle
• Benesch, Carsten
• Heinemann, Lutz
• Mader, Julia K
• Holzer, Manuel
• Kojzar, Harald
• Exall, Jane
• Yong, James
• Pichierri, Jennifer
• Barnard, Katharine D
• Kollman, Craig
• Cheng, Peiyao
• Hindmarsh, Peter C
• Campbell, Fiona M
• Arnolds, Sabine
• Pieber, Thomas R
• Evans, Mark L
• Dunger, David B
• Hovorka, Roman

Titel

Home Use of an Artificial Beta Cell in Type 1 Diabetes

Ist Teil von

• The New England journal of medicine, 2015-11, Vol.373 (22), p.2129-2140

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• In two randomized trials conducted under home conditions, investigators compared closed-loop insulin delivery with sensor-augmented pump therapy in adults and in children and adolescents for 12 weeks. The closed-loop approach improved glucose control and reduced hypoglycemia. Intensive insulin therapy is the standard of care for type 1 diabetes but is limited by the risk of hypoglycemia, 1 which leads to failure in achieving treatment goals for most patients in all age groups. 2 , 3 Among patients with type 1 diabetes, hypoglycemia is common, has a major effect on patients’ quality of life and psychological well-being, 4 and may cause seizures, which is of particular concern during the overnight hours in children and adolescents. 5 New approaches (e.g., continuous glucose monitoring) can improve glycemic control when the patient wears the sensors on a regular basis. 6 , 7 If insulin delivery is linked . . .